Polly Leontaridis-Kalogera – Managing Director, Italfarmaco Greece
Equipped with a strong business acumen, Italfarmaco (ITF) Hellas’ Managing Director, Polly Leontaridis-Kalogera…
Italfarmaco
Last updated: 13.02.2014
Address: V.le Fulvio Testi, 330, 20126 Milano,Italy
Tel: 02 64431
Web: http://www.italfarmaco.com/
Company description
Italfarmaco operates in both the pharmaceutical and the fine chemical industries and was founded in Milan in 1938.
The Italfarmaco Group now markets ethical products in Italy, Spain, Portugal and Greece, where it employs a workforce of over 1400 and has a total turnover exceeding 300 million euros.
The groups owns a plant in Milan, and a second in Madrid.
The Italfarmaco Group is particularly active in the field of research, mainly oriented towards the cardiovascular area and diseases associated with alterations of the immunological system.
In addition to its pharmaceutical activities in the field of ethical drugs, Italfarmaco also markets generic drugs through the company Lifepharma.
This business is mainly aimed at foreign markets, on some of which Lifepharma has its own offices and sales networks, as in the case of Russia.
In addition to research, production and marketing of drugs, the Italfarmaco Group manufactures active ingredients for the pharmaceutical industry through its subsidiary ‘Chemi S.p.A.’
Chemi S.p.A. sells some 90% of its products on foreign markets (USA, Japan, EU, etc.), on which it collaborates with many international pharmaceutical companies.
Products and services
Its therapeuticals areas are mainly cardiovascular, immuno-oncological, gynaecological, dermatological, orthopaedic and neurological areas.
Interviews
Interview with Francesco De Santis, President, Italfarmaco
Italfarmaco counts amongst the few players who really sustained the growth of the Italian pharmaceutical industry…
Related
Italy / Mandatory COVID-19 Vaccines for Healthcare Workers; Chiesi & Angelini’s AI Investments; Sputnik V Manufacturing
The latest from Italian pharma, including the government’s decision to make COVID-19 vaccines mandatory for all…
Italy / Stevanato’s $5 bn valuation; Zolgensma Approval; Sputnik V Manufacturing
The latest from Italian pharma, including the foreign minister’s plea for delivering on COVID-19 vaccine…
Italy / Menarini CEO on Averting Future Health Crises; Alfasigma Hackathon; January COVID Vaccines
A roundup of some of the most important recent stories from Italian pharma, including an in-depth interview with…
Pricing / Italy Takes Global Transparency Lead by Forcing Pharma to Disclose Public R&D Funding
In July 2020, Italy became the first country in the world to mandate pharma companies to disclose data surrounding…
News Roundup / Italy Pharma July 2020
Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline…
M&A / Menarini Makes Big US Oncology Move with Stemline Acquisition
Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US…
Internationalization / Chiesi Moves into Rare Diseases & the US Market
Italian mid-cap firm Chiesi is continuing its expansion in the USA market with the launch of a Boston-based…
Interview: Luca G. Guidotti – Deputy Scientific Director, San Raffaele…
Prof. Luca G. Guidotti discusses the esteemed positioning of San Raffaele within the global scientific community,…
Interview: Gianvito Martino – Scientific Director & Director of the…
The division of neuroscience at the San Raffaele Scientific Institute is one of the best worldwide performers in…
Interview: Angelo Corti – Director, Division of Experimental Oncology, San…
Professor Angelo Corti, Director of the Experimental Oncology division of the SRSI, discusses approaches to…
Interview: Paola Pozzi – Head, Office of Biotechnology Transfer, San…
Dr. Paola Pozzi, the head of the Office of Biotechnology Transfer at the San Raffaele Scientific Institute,…
Italian Pharma SMEs: Family Knows Best!
Italy’s traditional family-owned pharmaceutical companies are one of its greatest strengths; but these companies…
